Retrospective Study of the Use of Heparins in Pregnant Women and in vitro Testing on the HCT 116 Colorectal Carcinoma Cell Line

1. Middeldorp S, Naue C, Köhler C. Thrombophilia, thrombosis and thromboprophylaxis in pregnancy: for what and in whom?. Hamostaseologie. 2022;42(1):54–64. MiddeldorpS NaueC KöhlerC Thrombophilia, thrombosis and thromboprophylaxis in pregnancy: for what and in whom? Hamostaseologie 2022 42 1 54 64 Search in Google Scholar

2. Many A, Koren G. Low-molecular-weight heparins during pregnancy. Can Fam Physician. 2005;51(2):199–201. ManyA KorenG Low-molecular-weight heparins during pregnancy Can Fam Physician 2005 51 2 199 201 Search in Google Scholar

3. Hao C, Xu H, Yu L, Zhang L. Heparin: an essential drug for modern medicine. Prog Mol Biol Transl Sci. 2019;163:1–19. HaoC XuH YuL ZhangL Heparin: an essential drug for modern medicine Prog Mol Biol Transl Sci 2019 163 1 19 Search in Google Scholar

4. Wang P, Chi L, Zhang Z, Zhao H, Zhang F, Linhardt RJ. Heparin: An old drug for new clinical applications. Carbohydr Polym. 2022;119818. WangP ChiL ZhangZ ZhaoH ZhangF LinhardtRJ Heparin: An old drug for new clinical applications Carbohydr Polym 2022 119818 Search in Google Scholar

5. Lever WF, Smith PA, Hurley NA. Effects of intravenous heparin on the plasma lipoproteins in primary hypercholesteremic xanthomatosis and idiopathic hyperlipemia. Science. 1953;118(3074):653–4. LeverWF SmithPA HurleyNA Effects of intravenous heparin on the plasma lipoproteins in primary hypercholesteremic xanthomatosis and idiopathic hyperlipemia Science 1953 118 3074 653 4 Search in Google Scholar

6. Hernandez P, Passi N, Modarressi T, et al. Clinical Management of Hypertriglyceridemia in the Prevention of Cardiovascular Disease and Pancreatitis. Curr Atheroscler Rep. 2021;23(11):72. HernandezP PassiN ModarressiT Clinical Management of Hypertriglyceridemia in the Prevention of Cardiovascular Disease and Pancreatitis Curr Atheroscler Rep 2021 23 11 72 Search in Google Scholar

7. Real JT, Ascaso JF. Lipid metabolism and classification of hyperlipaemias. Clin Investig Arterioscler. 2021;33 Suppl 1:3–9. RealJT AscasoJF Lipid metabolism and classification of hyperlipaemias Clin Investig Arterioscler 2021 33 Suppl 1 3 9 Search in Google Scholar

8. Kuchay MS, Farooqui KJ, Bano T, Khandelwal M, Gill H, Mithal A. Heparin and insulin in the management of hypertriglyceridemia-associated pancreatitis: case series and literature review. Arch Endocrinol Metab. 2017;61:198–201. KuchayMS FarooquiKJ BanoT KhandelwalM GillH MithalA Heparin and insulin in the management of hypertriglyceridemia-associated pancreatitis: case series and literature review Arch Endocrinol Metab 2017 61 198 201 Search in Google Scholar

9. He W, Lu N. Emergent triglyceride-lowering therapy for hypertriglyceridemic pancreatitis. Hepatogastroenterology. 2015;62(138):429–34. HeW LuN Emergent triglyceride-lowering therapy for hypertriglyceridemic pancreatitis Hepatogastroenterology 2015 62 138 429 34 Search in Google Scholar

10. Joury A, Alshehri M, Mahendra A, Anteet M, Yousef MA, Khan AM. Therapeutic approaches in hypertriglyceridemia-induced acute pancreatitis: a literature review of available therapies and case series. J Clin Apher. 2020;35(2):131–7. JouryA AlshehriM MahendraA AnteetM YousefMA KhanAM Therapeutic approaches in hypertriglyceridemia-induced acute pancreatitis: a literature review of available therapies and case series J Clin Apher 2020 35 2 131 7 Search in Google Scholar

11. Fernandes CJ, Morinaga LT, Alves JL, et al. Cancer-associated thrombosis: the when, how and why. Eur Respir Rev. 2019;28(151). FernandesCJ MorinagaLT AlvesJL Cancer-associated thrombosis: the when, how and why Eur Respir Rev 2019 28 151 Search in Google Scholar

12. Kim AS, Khorana AA, McCrae KR. Mechanisms and biomarkers of cancer-associated thrombosis. Transl Res. 2020;225:33–53. KimAS KhoranaAA McCraeKR Mechanisms and biomarkers of cancer-associated thrombosis Transl Res 2020 225 33 53 Search in Google Scholar

13. Schaefer JK, Elshoury A, Nachar VR, Streiff MB, Lim MY. How to choose an appropriate anticoagulant for cancer-associated thrombosis. J Natl Compr Canc Netw. 2021;19(10):1203–10. SchaeferJK ElshouryA NacharVR StreiffMB LimMY How to choose an appropriate anticoagulant for cancer-associated thrombosis J Natl Compr Canc Netw 2021 19 10 1203 10 Search in Google Scholar

14. Cosmi B. An update on the efficacy and safety of novel anticoagulants for cancer associated thrombosis. Expert Opin Pharmacother. 2021;22(5):583–94. CosmiB An update on the efficacy and safety of novel anticoagulants for cancer associated thrombosis Expert Opin Pharmacother 2021 22 5 583 94 Search in Google Scholar

15. Smorenburg SM, Van Noorden CJ. The complex effects of heparins on cancer progression and metastasis in experimental studies. Pharmacol Rev. 2001;53(1):93–106. SmorenburgSM Van NoordenCJ The complex effects of heparins on cancer progression and metastasis in experimental studies Pharmacol Rev 2001 53 1 93 106 Search in Google Scholar

16. Ma SN, Mao ZX, Wu Y, et al. The anti-cancer properties of heparin and its derivatives: A review and prospect. Cell Adh Migr. 2020;14(1):118–28. MaSN MaoZX WuY The anti-cancer properties of heparin and its derivatives: A review and prospect Cell Adh Migr 2020 14 1 118 28 Search in Google Scholar

17. Cheng W, Dahmani FZ, Zhang J, et al. Anti-angiogenic activity and antitumor efficacy of amphiphilic twin drug from ursolic acid and low molecular weight heparin. Nanotechnology. 2017;28(7):075102. ChengW DahmaniFZ ZhangJ Anti-angiogenic activity and antitumor efficacy of amphiphilic twin drug from ursolic acid and low molecular weight heparin Nanotechnology 2017 28 7 075102 Search in Google Scholar

18. Bochenek J, Püsküllüoğlu M, Krzemieniecki K. The antineoplastic effect of low-molecular-weight heparins–a literature review. Contemp Oncol (Pozn). 2013;17(1):6–13. BochenekJ PüsküllüoğluM KrzemienieckiK The antineoplastic effect of low-molecular-weight heparins–a literature review Contemp Oncol (Pozn) 2013 17 1 6 13 Search in Google Scholar

19. Du S, Yu Y, Xu C, Xiong H, Yang S, Yao J. LMWH and its derivatives represent new rational for cancer therapy: construction strategies and combination therapy. Drug discovery today. 2019;24(10):2096–104. DuS YuY XuC XiongH YangS YaoJ LMWH and its derivatives represent new rational for cancer therapy: construction strategies and combination therapy Drug discovery today 2019 24 10 2096 104 Search in Google Scholar

20. Shi D, Sheng A, Chi L. Glycosaminoglycan-protein interactions and their roles in human disease. Front Mol Biosci. 2021;8:639666. ShiD ShengA ChiL Glycosaminoglycan-protein interactions and their roles in human disease Front Mol Biosci 2021 8 639666 Search in Google Scholar

21. Organization WH (WHO). The Global Cancer Observatory. 2021. https://gco.iarc.fr/today/ accesed on 01.10.2023 Organization WH (WHO) The Global Cancer Observatory 2021 https://gco.iarc.fr/today/ accesed on 01.10.2023 Search in Google Scholar

22. Cappell MS. Colon cancer during pregnancy. Gastroenterol Clin North Am. 2003;32(1):341–83. CappellMS Colon cancer during pregnancy Gastroenterol Clin North Am 2003 32 1 341 83 Search in Google Scholar

23. Dolghi A, Buzatu R, Dobrescu A, et al. Phytochemical analysis and in vitro cytotoxic activity against colorectal adenocarcinoma cells of Hippophae rhamnodies L., Cymbopogon citratus (DC) Stapf, and Ocimum basilicum L. essential oils. Plants (Basel). 2021;10(12):2752. DolghiA BuzatuR DobrescuA Phytochemical analysis and in vitro cytotoxic activity against colorectal adenocarcinoma cells of Hippophae rhamnodies L., Cymbopogon citratus (DC) Stapf, and Ocimum basilicum L. essential oils Plants (Basel) 2021 10 12 2752 Search in Google Scholar

24. Bremme KA. Haemostatic changes in pregnancy. Best Pract Res Clin Haematol. 2003;16(2):153–68. BremmeKA Haemostatic changes in pregnancy Best Pract Res Clin Haematol 2003 16 2 153 68 Search in Google Scholar

25. Aracic N, Roje D, Jakus IA, Bakotin M, Stefanovic V. The impact of inherited thrombophilia types and low molecular weight heparin treatment on pregnancy complications in women with previous adverse outcome. Yonsei Med J. 2016;57(5):1230–5. AracicN RojeD JakusIA BakotinM StefanovicV The impact of inherited thrombophilia types and low molecular weight heparin treatment on pregnancy complications in women with previous adverse outcome Yonsei Med J 2016 57 5 1230 5 Search in Google Scholar

26. Papadakis E, Pouliakis A, Aktypi A, et al. Low molecular weight heparins use in pregnancy: a practice survey from Greece and a review of the literature. Thromb J. 2019;17(1):1–4. PapadakisE PouliakisA AktypiA Low molecular weight heparins use in pregnancy: a practice survey from Greece and a review of the literature Thromb J 2019 17 1 1 4 Search in Google Scholar

27. Jaiswal A, Rashid M, Balek M, Park C. Acute myocardial infarction during pregnancy: a clinical checkmate. Indian Heart J. 2013;65(4):464–8. JaiswalA RashidM BalekM ParkC Acute myocardial infarction during pregnancy: a clinical checkmate Indian Heart J 2013 65 4 464 8 Search in Google Scholar

28. Benli AR, Benli NC, Usta AT, Atakul T, Koroglu M. Effect of maternal age on pregnancy outcome and cesarean delivery rate. J Clin Med Res. 2015;7(2):97. BenliAR BenliNC UstaAT AtakulT KorogluM Effect of maternal age on pregnancy outcome and cesarean delivery rate J Clin Med Res 2015 7 2 97 Search in Google Scholar

29. Sanson BJ, Lensing AW, Prins MH, et al. Safety of low-molecular-weight heparin in pregnancy: a systematic review. Thromb Haemost.1999;81(05):668–72. SansonBJ LensingAW PrinsMH Safety of low-molecular-weight heparin in pregnancy: a systematic review Thromb Haemost 1999 81 05 668 72 Search in Google Scholar

30. Greer IA, Nelson-Piercy C. Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood. 2005;106(2):401–7. GreerIA Nelson-PiercyC Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy Blood 2005 106 2 401 7 Search in Google Scholar

31. Galambosi PJ, Kaaja RJ, Stefanovic V, Ulander VM. Safety of low-molecular-weight heparin during pregnancy: a retrospective controlled cohort study. Eur J Obstet Gynecol Reprod Biol. 2012;163(2):154–9. GalambosiPJ KaajaRJ StefanovicV UlanderVM Safety of low-molecular-weight heparin during pregnancy: a retrospective controlled cohort study Eur J Obstet Gynecol Reprod Biol 2012 163 2 154 9 Search in Google Scholar

32. Yildiz Y, Özgü E, Unlu SB, Salman B, Eyi EG. The relationship between third trimester maternal hemoglobin and birth weight/length; results from the tertiary center in Turkey. J Matern Fetal Neonatal Med. 2014;27(7):729–32. YildizY ÖzgüE UnluSB SalmanB EyiEG The relationship between third trimester maternal hemoglobin and birth weight/length; results from the tertiary center in Turkey J Matern Fetal Neonatal Med 2014 27 7 729 32 Search in Google Scholar

33. Vermeulen T, Van de Velde M. The role of fibrinogen in postpartum hemorrhage. Best Pract Res Clin Anaesthesiol. 2022;36(3–4):399–410. VermeulenT Van de VeldeM The role of fibrinogen in postpartum hemorrhage Best Pract Res Clin Anaesthesiol 2022 36 3–4 399 410 Search in Google Scholar

34. Saeed Z, Shafi M, Saeed Z, Shafi M. Cancer in pregnancy. Obstet Gynecol Int. 2011;21(7):183–9. SaeedZ ShafiM SaeedZ ShafiM Cancer in pregnancy Obstet Gynecol Int 2011 21 7 183 9 Search in Google Scholar

35. Chatzinikolaou G, Nikitovic D, Berdiaki A, et al. Heparin regulates colon cancer cell growth through p38 mitogen-activated protein kinase signalling. Cell Prolif. 2010;43(1):9–18. ChatzinikolaouG NikitovicD BerdiakiA Heparin regulates colon cancer cell growth through p38 mitogen-activated protein kinase signalling Cell Prolif 2010 43 1 9 18 Search in Google Scholar

36. Dreyfuss JL, Regatieri CV, Lima MA, et al. A heparin mimetic isolated from a marine shrimp suppresses neovascularization. J Thromb Haemost. 2010;8(8):1828–37. DreyfussJL RegatieriCV LimaMA A heparin mimetic isolated from a marine shrimp suppresses neovascularization J Thromb Haemost 2010 8 8 1828 37 Search in Google Scholar

37. Solayar GN, Walsh PM, Mulhall KJ. The effect of a new direct Factor Xa inhibitor on human osteoblasts: an in-vitro study comparing the effect of rivaroxaban with enoxaparin. BMC Musculoskelet Disord. 2011;12:1–8. SolayarGN WalshPM MulhallKJ The effect of a new direct Factor Xa inhibitor on human osteoblasts: an in-vitro study comparing the effect of rivaroxaban with enoxaparin BMC Musculoskelet Disord 2011 12 1 8 Search in Google Scholar

38. Bittkau KS, Dörschmann P, Blümel M, et al. Comparison of the effects of fucoidans on the cell viability of tumor and non-tumor cell lines. Mar Drugs. 2019;17(8):441. BittkauKS DörschmannP BlümelM Comparison of the effects of fucoidans on the cell viability of tumor and non-tumor cell lines Mar Drugs 2019 17 8 441 Search in Google Scholar

39. Lean QY, Patel RP, Stewart N, Sohal SS, Gueven N. Identification of pro-and anti-proliferative oligosaccharides of heparins. Integr Biol (Camb). 2014;6(1):90–9. LeanQY PatelRP StewartN SohalSS GuevenN Identification of pro-and anti-proliferative oligosaccharides of heparins Integr Biol (Camb) 2014 6 1 90 9 Search in Google Scholar

40. Alban S. Pharmacological strategies for inhibition of thrombin activity. Curr Pharm Des. 2008;14(12):1152–75. AlbanS Pharmacological strategies for inhibition of thrombin activity Curr Pharm Des 2008 14 12 1152 75 Search in Google Scholar

41. Jayson GC, Gallagher JT. Heparin oligosaccharides: inhibitors of the biological activity of bFGF on Caco-2 cells. Br J Cancer. 1997;75(1):9–16. JaysonGC GallagherJT Heparin oligosaccharides: inhibitors of the biological activity of bFGF on Caco-2 cells Br J Cancer 1997 75 1 9 16 Search in Google Scholar

42. Yakusheva AA, Filkova AA. The role of platelets in tumor cell metastasis. Pediatric Hematology/Oncology and Immunopathology. 2021;20(4):185–190. YakushevaAA FilkovaAA The role of platelets in tumor cell metastasis Pediatric Hematology/Oncology and Immunopathology 2021 20 4 185 190 Search in Google Scholar

43. Karpatkin S, Pearlstein E. Role of platelets in tumor cell metastases. Ann Intern Med. 1981;95(5):636–41. KarpatkinS PearlsteinE Role of platelets in tumor cell metastases Ann Intern Med 1981 95 5 636 41 Search in Google Scholar

44. Gasic GJ. Role of plasma, platelets, and endothelial cells in tumor metastasis. Cancer Metastasis Rev. 1984;3:99–114. GasicGJ Role of plasma, platelets, and endothelial cells in tumor metastasis Cancer Metastasis Rev 1984 3 99 114 Search in Google Scholar

45. Ludwig RJ, Boehme B, Podda M, et al. Endothelial P-selectin as a target of heparin action in experimental melanoma lung metastasis. Cancer Res. 2004;64(8):2743–50. LudwigRJ BoehmeB PoddaM Endothelial P-selectin as a target of heparin action in experimental melanoma lung metastasis Cancer Res 2004 64 8 2743 50 Search in Google Scholar

46. Varki NM, Varki A. Heparin inhibition of selectin-mediated interactions during the hematogenous phase of carcinoma metastasis: rationale for clinical studies in humans. Semin Thromb Hemost. 2002;28(1):53–66. VarkiNM VarkiA Heparin inhibition of selectin-mediated interactions during the hematogenous phase of carcinoma metastasis: rationale for clinical studies in humans Semin Thromb Hemost 2002 28 1 53 66 Search in Google Scholar

47. Hostettler N, Naggi A, Torri G, et al. P-selectin-and heparanase-dependent antimetastatic activity of non-anticoagulant heparins. The FASEB Journal. 2007;21(13):3562–72. HostettlerN NaggiA TorriG P-selectin-and heparanase-dependent antimetastatic activity of non-anticoagulant heparins The FASEB Journal 2007 21 13 3562 72 Search in Google Scholar

48. Alam F, Al-Hilal TA, Chung SW, et al. Oral delivery of a potent anti-angiogenic heparin conjugate by chemical conjugation and physical complexation using deoxycholic acid. Biomaterials. 2014;35(24):6543–52. AlamF Al-HilalTA ChungSW Oral delivery of a potent anti-angiogenic heparin conjugate by chemical conjugation and physical complexation using deoxycholic acid Biomaterials 2014 35 24 6543 52 Search in Google Scholar

49. Daneshmand M, Parolin DA, Hirte HW, et al. A pharmacodynamic study of the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in metastatic colorectal cancer patients. Clin. Cancer Res. 2003;9(7):2457–64. DaneshmandM ParolinDA HirteHW A pharmacodynamic study of the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in metastatic colorectal cancer patients Clin. Cancer Res. 2003 9 7 2457 64 Search in Google Scholar

50. Weissmann M, Bhattacharya U, Feld S, Hammond E, Ilan N, Vlodavsky I. The heparanase inhibitor PG545 is a potent anti-lymphoma drug: Mode of action. Matrix Biol. 2019;77:58–72. WeissmannM BhattacharyaU FeldS HammondE IlanN VlodavskyI The heparanase inhibitor PG545 is a potent anti-lymphoma drug: Mode of action Matrix Biol 2019 77 58 72 Search in Google Scholar

51. Yin W, Zhang J, Jiang Y, Juan S. Combination therapy with low molecular weight heparin and Adriamycin results in decreased breast cancer cell metastasis in C3H mice. Exp Ther Med. 2014;8(4):1213–8. YinW ZhangJ JiangY JuanS Combination therapy with low molecular weight heparin and Adriamycin results in decreased breast cancer cell metastasis in C3H mice Exp Ther Med 2014 8 4 1213 8 Search in Google Scholar

52. Braumann C, Ordemann J, Kilian M, Wenger FA, Jacobi CA. Local and systemic chemotherapy with taurolidine and taurolidine/heparin in colon cancer-bearing rats undergoing laparotomy. Clin Exp Metastasis. 2003;20:387–94. BraumannC OrdemannJ KilianM WengerFA JacobiCA Local and systemic chemotherapy with taurolidine and taurolidine/heparin in colon cancer-bearing rats undergoing laparotomy Clin Exp Metastasis 2003 20 387 94 Search in Google Scholar